XML 125 R111.htm IDEA: XBRL DOCUMENT v3.25.0.1
GOODWILL AND OTHER INTANGIBLE ASSETS - Narrative (Details) - USD ($)
$ in Millions
 1 Months Ended 3 Months Ended 12 Months Ended
Jan. 31, 2024
Dec. 31, 2024
Jun. 30, 2024
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Other intangible assets            
Payment for contingent consideration liability $ 400          
Finite-lived intangible assets, period increase (decrease)         $ 511  
Amortization of intangible assets       $ 9,000 9,200 $ 9,700
Future estimated amortization, 2025   $ 3,500   3,500    
Future estimated amortization, 2026   1,900   1,900    
Future estimated amortization, 2027   1,900   1,900    
Future estimated amortization, 2028   1,800   1,800    
Future estimated amortization, 2029   $ 1,700   1,700    
Intangible asset impairment       $ 2,900 $ 136 $ 101
Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration]       Cost of products sold    
Impairment, Intangible Asset, Indefinite-Lived (Excluding Goodwill), Statement of Income or Comprehensive Income [Extensible Enumeration]   Research and development Research and development      
Impairment, Intangible Asset, Statement of Income or Comprehensive Income [Extensible Enumeration]       Other intangible assets    
Lower Revised Cash Flow Projections for Augtyro | Augtyro            
Other intangible assets            
Impairment charge   $ 1,400        
Reduced Cash Flow Forecast for Abecma | Abecma            
Other intangible assets            
Impairment charge   122        
Lower Revised Cash Flow Projections for Inrebic | Inrebic            
Other intangible assets            
Impairment charge     $ 280      
Investigational Compound for Immunologic Diseases | Celgene            
Other intangible assets            
IPRD impairment charge   $ 390        
Investigational Compound for Hematologic Diseases | Celgene            
Other intangible assets            
IPRD impairment charge     $ 590